Obesity drug rivals aim to unseat Zepbound, Ozempic – Indianapolis Business Journal
Eli Lilly and Novo are leading now, but there are multiple drug candidates waiting in the wings that could disrupt that duopoly in the future.
Eli Lilly Goldman Sachs Sam Fazeli Boehringer Ingelheim Zealand Pharma Boehringer Ingelheim Gmb John Murphy
Source: ibj.com